ScreenerHero

ALSEN Sensorion SA

EPA · FR · Healthcare · Biotechnology · sensorion.com
6.280EUR-4.99%Mkt Cap: 70.35M $P/E: —

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy developm…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap70.35M USD
Enterprise Value-18.67M USD
Revenue (TTM)6.69M USD
Gross Profit6.69M USD
Net Income (TTM)-31.99M USD
Revenue/Share0.79 EUR
Last Price6.280 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees66
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012596468
Valuation
P/E (Trailing)—
P/E (Forward)-2.86
PEG—
EV/EBITDA0.50
EV/Revenue-2.79
P/S11.07
P/B0.84
EPS (TTM)-4.65
EPS (Forward)-2.31
52W Range
5.8181% of range40.40
52W High40.40 EUR
52W Low5.818 EUR
Profitability
Gross Margin100.00%
Oper. Margin-802.92%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.16%
ROA-50.84%
Growth
Revenue Growth14.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.65M USD
CapEx (TTM)821.74K USD
FCF Margin-285.75%
FCF Yield-27.17%
Net Debt-92.71M USD
Net Debt/EBITDA2.48
Balance Sheet
Debt/Equity0.03
Current Ratio8.00
Quick Ratio7.91
Book Value/Sh7.92 EUR
Cash/Share8.59 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateSep 15, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)40.20 EUR
Upside (mean)+540.1%
Target Range32.00 EUR – 50.00 EUR
32.00+540.1% to mean50.00
# Analysts5
Ownership
Shares Out.10.31M
Float6.02M
Insiders34.76%
Institutions35.45%
Technical
SMA 5011.91 (-47.3%)
SMA 20016.31 (-61.5%)
Beta0.41
S&P 52W Chg14.58%
Avg Vol (30d)19.05K
Avg Vol (10d)30.02K
Technical Indicators
RSI (14)17.9
MACD-1.5488
MACD Signal-1.4248
MACD Hist.-0.1240
BB Upper13.25 EUR
BB Middle9.292 EUR
BB Lower5.337 EUR
BB Width85.13%
ATR (14)0.6631 EUR
Vol Ratio (20d)2.06x